| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9979442 | The Journal of Thoracic and Cardiovascular Surgery | 2005 | 6 Pages |
Abstract
Isolated lung perfusion monotherapy or combination therapy with gemcitabine, cisplatin, or melphalan resulted in significantly longer survival compared with that seen in control animals. Isolated lung perfusion combination therapy with melphalan-gemcitabine resulted in the best survival either in vitro or in vivo.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Bart P. PhD, Jeroen M.H. PhD, Sander MD, Bea PhD, Jan B. PhD, Paul E.Y. PhD,